Evidence for Metabolic Hypothalamo-Amygdala Dysfunction in Narcolepsy | Zendy

Rositsa Poryazova | Zendy; Betina Schnepf | Zendy; Esther Werth | Zendy; Ramin Khatami | Zendy; Ulrike Dydak | Zendy; D. Meier | Zendy; Peter Boesiger | Zendy; Claudio L. Bassetti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evidence for Metabolic Hypothalamo-Amygdala Dysfunction in Narcolepsy

Author(s) -

Rositsa Poryazova,

Betina Schnepf,

Esther Werth,

Ramin Khatami,

Ulrike Dydak,

D. Meier,

Peter Boesiger,

Claudio L. Bassetti

Publication year - 2009

Publication title -

sleep

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.222

H-Index - 207

eISSN - 1550-9109

pISSN - 0161-8105

DOI - 10.1093/sleep/32.5.607

Subject(s) - narcolepsy , medicine , neurology , endocrinology , modafinil , psychology , psychiatry

Proton resonance spectroscopy (1H-MRS) allows noninvasive chemical tissue analysis in the living brain. As neuronal loss and gliosis have been described in narcolepsy, metabolites of primary interest are N-acetylaspartate (NAA), a marker of neuronal integrity and myo-Inositol (ml), a glial marker and second messenger involved in the regulation of intracellular calcium. One 1H-MRS study in narcolepsy found no metabolic changes in the pontomedullary junction. Another study showed a reduction in NAA/creatine-phosphocreatine (Cr) in the hypothalamus of narcolepsy patients with cataplexy. We aimed to test for metabolic changes in specific brain areas, "regions of interest," thought to be involved in emotional processing, sleep regulation and pathophysiology of narcolepsy: hypothalamus, pontomesencephalic junction and both amygdalae.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research